BridgeBio Pharma Inc
BBIO
Company Profile
Business description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact
3160 Porter Drive
Suite 250
Palo AltoCA94304
USAT: +1 650 391-9740
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
730
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,142.00 | 63.40 | -0.69% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 26,523.07 | 509.47 | -1.88% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 57,268.49 | 371.35 | -0.64% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,832.76 | 108.71 | -1.57% |
| S&P/ASX 200 | 8,920.40 | 52.50 | -0.59% |
| SSE Composite Index | 4,109.19 | 24.82 | -0.60% |